将患者的观点纳入结构化利益风险评估:药物开发框架建议
Emuella Flood1, Niklas Karlsson2, Jennifer Ostridge3
1Patient Centered Science, BioPharmaceuticals Medical Evidence, AstraZeneca, Gaithersburg, MD, USA.
Therapeutic innovation & regulatory science
|March 9, 2026
概括
监管机构寻求患者的意见,以评估药物的益处与风险. 这项研究建议扩大框架,在药物开发过程中系统地纳入患者的观点,以获得更好的结果.
科学领域:
- 药监和药物开发 药物监督和药物开发
- 监管科学 监管科学
- 以患者为中心的研究
背景情况:
- 监管机构主张将患者的观点纳入利益风险评估,以使决策与患者需求保持一致.
- 目前的方法主要依赖于患者报告的临床试验结果,缺乏系统的方法.
- 需要全面的框架,在整个药物开发生命周期中纳入患者的见解.
研究的目的:
- 建议扩展沙利文等人. 结构化利益与风险 (SBR) 评估框架.
- 加强在药物开发的所有阶段系统地纳入患者的观点.
- 在监管决策中培养以患者为中心的方法.
主要方法:
- 审查和分析现有的利益风险评估框架.
- 建立在2023年沙利文等人的基础上 的 sBR 评估框架.
- 制定建议,在药物开发的每个阶段整合患者的观点.
主要成果:
- 在当前的系统性利益风险 (sBR) 评估中发现患者输入方面的差距.
- 建议扩大sBR框架,在药物开发过程中纳入患者的观点.
- 为更以患者为中心的药物开发生命周期提出建议.
结论:
- 在以患者为中心的药物开发中,系统地将患者的观点纳入益处风险评估是至关重要的.
- 扩大现有的sBR框架可以促进更全面地纳入患者见解.
- 这种方法旨在改善治疗结果并改善患者的生活.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
515
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
515
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
58
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
58
Biopharmaceutical Factors Influencing Drug Product Design: Overview
395
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
395
Structure-Activity Relationships and Drug Design
1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Pharmacovigilance
1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
Drug Administration and Therapy Phases: Overview
1.6K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.6K


